Developer docs
API playgroundTry for free, no card

Search company profiles

Epirium Bio

Full company profile

uuid0000gt8

Namestring
Epirium Bio
Legal namestring
Epirium Bio
Websiteurl
epirium.com
Company typeenum
Private
Founded yearint
2008
Descriptiontext

Epirium Bio is a clinical-stage biopharmaceutical company headquartered in San Diego, California, founded in 2008 and previously operating as Cardero Therapeutics, Inc. The company has built an IP-protected platform of orally bioavailable small molecules that inhibit the 15-PGDH enzyme, a "gerozyme" that degrades prostaglandin E2 (PGE-2) and rises with age. By restoring PGE-2 signaling, the platform aims to re-establish tissue homeostasis, resolve aberrant inflammation, stimulate regeneration, and reduce fibrosis across neuromuscular and inflammatory diseases.

The company's lead candidate, MF-300, is a first-in-class oral 15-PGDH enzyme inhibitor currently advancing into a Phase 2b trial in sarcopenia (age-related muscle weakness), supported by a completed Phase 1 trial in 88 participants that demonstrated target engagement, tolerability, and safety in healthy volunteers and older adults. The pipeline additionally includes EPM-01, an oral compound targeting mitochondrial dysfunction in Becker muscular dystrophy that has completed Phase 1, and MF-1305, an oral 15-PGDH inhibitor in IND-enabling studies for inflammatory bowel disease. Preclinical efficacy has been generated across spinal muscular atrophy and idiopathic pulmonary fibrosis, signaling platform breadth.

Epirium Bio operates a pre-revenue pharmaceutical development model: it generates no current product revenue and will monetize via traditional pharmaceutical commercialization (wholesalers, specialty pharmacies, hospital networks) following FDA approval of MF-300 and pipeline assets. The company is backed by $85 million in Series A financing from ARCH Venture Partners, Longitude Capital, Bluebird Ventures, Adams Street Partners, Vertex Ventures HC, Longevity Fund, and Horizons Ventures. Recent FDA milestones include IND clearance for MF-300 (December 2024) and a positive Type C meeting outcome (January 2026), positioning the Phase 2b trial initiation for mid-2026.

Short descriptiontext

Epirium Bio is a clinical-stage biopharmaceutical company developing orally bioavailable small molecule 15-PGDH inhibitors that restore PGE-2 signaling. Its lead candidate MF-300 is in Phase 2b for sarcopenia, with additional programs in Becker muscular dystrophy and inflammatory bowel disease.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSan Diego, United States
HQ citystring
San Diego
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
small molecule therapeutics, 15-PGDH inhibitors, sarcopenia treatment drugs, neuromuscular disease therapeutics, biopharmaceutical drug development
Industry1 code
PRIMARYHLAAAGAL
Regenerative Immunology & Inflammation Modulation (pro-regenerative biologics)
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Biopharmaceutical Drug Development
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Pharmaceutical Drug Development and Commercialization
TypeOne Time License
Description

Pre-revenue biopharmaceutical company developing small molecule drugs for neuromuscular diseases (sarcopenia, Becker muscular dystrophy, SMA) and inflammatory/fibrotic diseases (IBD, IPF). Revenue will be generated upon FDA approval and commercialization of MF-300 and pipeline candidates.

epirium.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Epirium Bio develops an IP-protected platform of orally bioavailable small molecules that leverage PGE-2 signaling to restore tissue homeostasis, resolve inflammation, and stimulate regeneration. Its lead candidate, MF-300, is a first-in-class oral 15-PGDH enzyme inhibitor currently in Phase 2b for sarcopenia, with additional pipeline candidates targeting Becker muscular dystrophy (EPM-01), inflammatory bowel disease (MF-1305), and other neuromuscular and fibrotic indications.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Phase 1 results demonstrated target engagement, good tolerability, and safety in healthy volunteers and older adults (88 participants)
+2 more records
Product overview1 text field

Epirium Bio is a biopharmaceutical company with an IP-protected platform of orally bioavailable small molecules leveraging PGE-2 signaling to restore tissue homeostasis. The company's core product portfolio includes: MF-300 (Phase 2b for sarcopenia), a first-in-class oral 15-PGDH enzyme inhibitor; EPM-01 (completed Phase 1 for Becker muscular dystrophy); and MF-1305 (IND enabling for IBD). The platform has generated preclinical efficacy data across indications including spinal muscular atrophy (SMA), irritable bowel disease (IBD), and idiopathic pulmonary fibrosis (IPF).

Product and service3 records
1MF-300
CategoryLead Clinical Candidate (Sarcopenia)
Description

First-in-class oral small molecule 15-PGDH enzyme inhibitor under development for the treatment of sarcopenia (age-related muscle weakness). Currently advancing through Phase 2b clinical trials with demonstrated target engagement, safety, and tolerability in Phase 1 trials involving 88 participants.

2EPM-01
CategoryPipeline Candidate (Becker Muscular Dystrophy)
Description

Novel, oral, synthetic compound targeting mitochondrial dysfunction for the treatment of Becker muscular dystrophy, with demonstrated proof-of-concept in multiple preclinical and clinical studies.

3MF-1305
CategoryPipeline Candidate (Inflammatory Bowel Disease)
Description

Oral 15-PGDH inhibitor in IND-enabling stage for inflammatory bowel disease, including ulcerative colitis and Crohn's disease.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierMinorTypeStrategic or Co-development Partner
Description

The largest nonprofit organization in the United States focused on finding a cure for Duchenne muscular dystrophy. Partnered for patient resources and clinical trial support.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Nonprofit health agency committed to transforming lives of people living with muscular dystrophy, ALS, and related neuromuscular diseases. Has committed more than $1 billion to research.

Recent move9 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Market position
Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors8 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Epirium Bio

Biopharmaceutical Drug Developmentepirium.com

Epirium Bio is a clinical-stage biopharmaceutical company developing orally bioavailable small molecule 15-PGDH inhibitors that restore PGE-2 signaling. Its lead candidate MF-300 is in Phase 2b for sarcopenia, with additional programs in Becker muscular dystrophy and inflammatory bowel disease.

What Epirium Bio does

Epirium Bio is a clinical-stage biopharmaceutical company headquartered in San Diego, California, founded in 2008 and previously operating as Cardero Therapeutics, Inc. The company has built an IP-protected platform of orally bioavailable small molecules that inhibit the 15-PGDH enzyme, a "gerozyme" that degrades prostaglandin E2 (PGE-2) and rises with age. By restoring PGE-2 signaling, the platform aims to re-establish tissue homeostasis, resolve aberrant inflammation, stimulate regeneration, and reduce fibrosis across neuromuscular and inflammatory diseases.

The company's lead candidate, MF-300, is a first-in-class oral 15-PGDH enzyme inhibitor currently advancing into a Phase 2b trial in sarcopenia (age-related muscle weakness), supported by a completed Phase 1 trial in 88 participants that demonstrated target engagement, tolerability, and safety in healthy volunteers and older adults. The pipeline additionally includes EPM-01, an oral compound targeting mitochondrial dysfunction in Becker muscular dystrophy that has completed Phase 1, and MF-1305, an oral 15-PGDH inhibitor in IND-enabling studies for inflammatory bowel disease. Preclinical efficacy has been generated across spinal muscular atrophy and idiopathic pulmonary fibrosis, signaling platform breadth.

Epirium Bio operates a pre-revenue pharmaceutical development model: it generates no current product revenue and will monetize via traditional pharmaceutical commercialization (wholesalers, specialty pharmacies, hospital networks) following FDA approval of MF-300 and pipeline assets. The company is backed by $85 million in Series A financing from ARCH Venture Partners, Longitude Capital, Bluebird Ventures, Adams Street Partners, Vertex Ventures HC, Longevity Fund, and Horizons Ventures. Recent FDA milestones include IND clearance for MF-300 (December 2024) and a positive Type C meeting outcome (January 2026), positioning the Phase 2b trial initiation for mid-2026.

Epirium Bio firmographics

Firmographics
Name
Epirium Bio
Legal name
Epirium Bio
Website
https://epirium.com
Company type
Private
Founded year
2008
Operating status
Operating
Headcount range
11–50 employees
Short description
Epirium Bio is a clinical-stage biopharmaceutical company developing orally bioavailable small molecule 15-PGDH inhibitors that restore PGE-2 signaling. Its lead candidate MF-300 is in Phase 2b for sarcopenia, with additional programs in Becker muscular dystrophy and inflammatory bowel disease.
Ownership category
akta.pro rank

Epirium Bio industry classification

Industry
Product category
Biopharmaceutical Drug Development
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAAGAL
Regenerative Immunology & Inflammation Modulation (pro-regenerative biologics)
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering

Keywords

  • Small molecule therapeutics
  • 15-PGDH inhibitors
  • Sarcopenia treatment drugs
  • Neuromuscular disease therapeutics
  • Biopharmaceutical drug development

Where Epirium Bio is headquartered

Location

Headquarters

HQ city
San Diego
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Epirium Bio business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

  1. Pharmaceutical Drug Development and Commercialization: Pre-revenue biopharmaceutical company developing small molecule drugs for neuromuscular diseases (sarcopenia, Becker muscular dystrophy, SMA) and inflammatory/fibrotic diseases (IBD, IPF). Revenue will be generated upon FDA approval and commercialization of MF-300 and pipeline candidates.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Epirium Bio product offering

Product offering

Core offering

Epirium Bio develops an IP-protected platform of orally bioavailable small molecules that leverage PGE-2 signaling to restore tissue homeostasis, resolve inflammation, and stimulate regeneration. Its lead candidate, MF-300, is a first-in-class oral 15-PGDH enzyme inhibitor currently in Phase 2b for sarcopenia, with additional pipeline candidates targeting Becker muscular dystrophy (EPM-01), inflammatory bowel disease (MF-1305), and other neuromuscular and fibrotic indications.

Product overview

Epirium Bio is a biopharmaceutical company with an IP-protected platform of orally bioavailable small molecules leveraging PGE-2 signaling to restore tissue homeostasis. The company's core product portfolio includes: MF-300 (Phase 2b for sarcopenia), a first-in-class oral 15-PGDH enzyme inhibitor; EPM-01 (completed Phase 1 for Becker muscular dystrophy); and MF-1305 (IND enabling for IBD). The platform has generated preclinical efficacy data across indications including spinal muscular atrophy (SMA), irritable bowel disease (IBD), and idiopathic pulmonary fibrosis (IPF).

Differentiator

Problem solved

Functional benefit

Products and services

  • MF-300 First-in-class oral small molecule 15-PGDH enzyme inhibitor under development for the treatment of sarcopenia (age-related muscle weakness). Currently advancing through Phase 2b clinical trials with demonstrated target engagement, safety, and tolerability in Phase 1 trials involving 88 participants.
  • EPM-01 Novel, oral, synthetic compound targeting mitochondrial dysfunction for the treatment of Becker muscular dystrophy, with demonstrated proof-of-concept in multiple preclinical and clinical studies.
  • MF-1305 Oral 15-PGDH inhibitor in IND-enabling stage for inflammatory bowel disease, including ulcerative colitis and Crohn's disease.

Quantifiable outcome

  • Phase 1 results demonstrated target engagement, good tolerability, and safety in healthy volunteers and older adults (88 participants)
  • +2 more outcomes

Companies that use Epirium Bio

Customer profile

Segments5 records

Ideal customer profiles2 records

Epirium Bio technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Epirium Bio partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered minor.

  • Parent Project Muscular Dystrophy (PPMD)minorStrategic or Co-development PartnerThe largest nonprofit organization in the United States focused on finding a cure for Duchenne muscular dystrophy. Partnered for patient resources and clinical trial support.
  • Muscular Dystrophy Association (MDA)minorStrategic or Co-development PartnerNonprofit health agency committed to transforming lives of people living with muscular dystrophy, ALS, and related neuromuscular diseases. Has committed more than $1 billion to research.

Scale indicators4 records

Recent moves9 records

Expansion highlights6 records

Epirium Bio competitors and assessment

Company assessment

Market position

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Epirium Bio social profiles

Digital presence

Epirium Bio financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Epirium Bio leadership team

Management profile

Number of profiles

Profiles6 records

Epirium Bio funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors8 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Epirium Bio M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Epirium Bio

What does Epirium Bio do?

Epirium Bio develops an IP-protected platform of orally bioavailable small molecules that leverage PGE-2 signaling to restore tissue homeostasis, resolve inflammation, and stimulate regeneration. Its lead candidate, MF-300, is a first-in-class oral 15-PGDH enzyme inhibitor currently in Phase 2b for sarcopenia, with additional pipeline candidates targeting Becker muscular dystrophy (EPM-01), inflammatory bowel disease (MF-1305), and other neuromuscular and fibrotic indications.

Is Epirium Bio a public or private company?

Epirium Bio is a private company. It is classified as venture growth investor backed and is currently operating.

When was Epirium Bio founded?

Epirium Bio was founded in 2008. It employs 11 to 50 people.

Where is Epirium Bio based?

Epirium Bio is headquartered in San Diego, United States, in the North America region.

How does Epirium Bio make money?

One revenue line is on record: pharmaceutical Drug Development and Commercialization.

Does Epirium Bio have an API?

No public API is recorded for Epirium Bio.

What industry is Epirium Bio in?

Epirium Bio's product category is Biopharmaceutical Drug Development. Its primary akta.pro industry code is HLAAAGAL, Regenerative Immunology & Inflammation Modulation (pro-regenerative biologics). Its NAICS code is 541714 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
The Cool DownFor worn-out knees, the usual answer was replacement — until one injection regrew cartilageStanford Medicine researchers published a study in Science showing that a one-time injection targeting the enzyme 15-PGDH, which increases with age, not only rebuilt damaged cartilage in older mice but also prevented arthritis in approximately half of them. In separate lab tests on human cartilage cells from knee replacement patients, the same inhibitor treatment caused the cells to begin producing new cartilage. The 15-PGDH inhibitor has already moved into Phase 1 testing through Epirium Bio for age-related muscle weakness, with early data indicating it is safe and pharmacologically active in healthy volunteers.BioWorldEpirium’s 15-PGDH inhibitor IBD candidates improve disease outcomes in modelsEpirium Bio Inc. developed small-molecule 15-PGDH inhibitors MF-300 and MF-1305 for inflammatory bowel disease. MF-300 is phase II-ready, while MF-1305 is preclinical. The company reports these candidates improve disease outcomes in models.SdbnEpirium Bio Presenting New Preclinical Data on its 15-PGDH Inhibitor Program in Inflammatory Bowel Disease at Digestive Disease Week® 2026 – San Diego Biotechnology NetworkEpirium Bio is presenting new preclinical data on its oral 15-PGDH inhibitor program for inflammatory bowel disease at Digestive Disease Week 2026. The data includes results on MF-300 and MF-1305 in mouse colitis models, showing significant improvements in disease markers.BioSpaceEpirium Bio Presenting New Preclinical Data on its 15-PGDH Inhibitor Program in Inflammatory Bowel Disease at Digestive Disease Week® 2026Epirium Bio presented preclinical data on its oral 15-PGDH inhibitors MF-300 and MF-1305 at Digestive Disease Week 2026, showing improved endoscopic scores, reduced cytokines, and better histology in colitis mouse models. MF-300, a Phase 2-ready compound, improved endoscopic measures at all doses, while MF-1305 improved disease activity and histology, exceeding cyclosporine in some endpoints.Business Wire BlogEpirium Bio Presenting New Preclinical Data on its 15-PGDH Inhibitor Program in Inflammatory Bowel Disease at Digestive Disease Week® 2026Epirium Bio presented preclinical data on its 15-PGDH inhibitors MF-300 and MF-1305 in inflammatory bowel disease at Digestive Disease Week 2026. In mouse colitis models, both compounds improved disease severity markers, with MF-300 showing endoscopic improvement and MF-1305 improving disease activity and histology. The company plans to advance MF-300 into Phase 2b for sarcopenia.openPR.comBecker Muscular Dystrophy Pipeline 2026: Therapies Under Investigation, Clinical Trials Milestones, and FDA Approvals by DelveInsight | Epirium Bio, Immuno Forge, Italfarmaco, Santhera PharmaceuticalsEdgewise Therapeutics announced positive results from its MESA open-label extension trial for sevasemten in Becker and Duchenne muscular dystrophy in June 2025, with 99% of eligible participants enrolling as of the March 2025 data cutoff. The U.S. FDA granted orphan drug designation to IPS Heart's GIVI-MPC stem cell therapy for Becker muscular dystrophy in January 2025, offering tax incentives and seven years of market exclusivity upon approval. Multiple companies including Epirium Bio, Immuno Forge, Italfarmaco, Santhera Pharmaceuticals, and Edgewise Therapeutics are developing therapies such as EPM-01, PF1801, Givinostat, Vamorolone, and EDG 5506 across various clinical trial phases.BioSpaceEpirium Bio to Present New MF-300 Clinical and Translational Data at the Intrinsic Capacity, Frailty and Sarcopenia Research Conference 2026Epirium Bio announced it will present new Phase 1 clinical and translational data for its investigational drug MF-300 at the Intrinsic Capacity, Frailty and Sarcopenia Research Conference 2026 in Washington, DC on March 12. The Phase 1 study of 88 participants demonstrated that MF-300 was safe and well tolerated with no dose-limiting toxicities, showed clear target engagement through dose-related biomarker changes, and achieved clinically relevant PGE2 increases in 75-100% of participants. The company plans to initiate a randomized, placebo-controlled Phase 2b trial in patients with age-related sarcopenia in the second half of 2026.BioSpaceEpirium Bio Announces Follow-on Phase 1 Results in Older Adult Participants for MF-300, a First-In-Class, Oral 15-PGDH Enzyme Inhibitor, for the Treatment of SarcopeniaEpirium Bio announced that its Phase 1 trial for MF-300, an oral enzyme inhibitor targeting sarcopenia, met its primary safety endpoint in older adult participants with no dose-limiting toxicities. The results demonstrated favorable pharmacokinetic and pharmacodynamic profiles consistent with younger cohorts, supporting the drug's potential to increase muscle strength. Consequently, the company plans to initiate a Phase 2 clinical trial for age-related sarcopenia in mid-2026.BioSpaceEpirium Bio Completes Dosing in First-In-Human Phase 1 Clinical Trial Evaluating MF-300, A First-In-Class, Oral 15-PGDH Enzyme Inhibitor, For the Treatment of SarcopeniaEpirium Bio Inc. has completed dosing in its Phase 1 clinical trial for MF-300, an investigational oral inhibitor targeting sarcopenia. Preliminary results indicate the drug was safe and well-tolerated with no serious adverse events reported. The company expects to release top-line data later this quarter ahead of a projected Phase 2 trial enrollment in mid-2026.BioSpaceEpirium Bio Announces First Participants Dosed in Phase 1 Clinical Trial in Healthy Volunteers, Evaluating MF-300, a First-In-Class, Oral 15-PGDH Enzyme Inhibitor, for the Treatment of SarcopeniaEpirium Bio has initiated dosing of healthy volunteers in its Phase 1 clinical trial for MF-300, an investigational oral therapy targeting sarcopenia. The company anticipates reporting top-line results from this dose-escalation study in the second half of 2025.